We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In.
Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks
TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock. Earlier on May 7, Grifols, S.A. (NASDAQ:GRFS) reported its results for the first quarter of 2026. The company recorded total revenue of €1.7 billion, reflecting a 3.3% increase on a constant currency basis compared with the prior year.
Growth was primarily driven by its Biopharma segment, which advanced 6.8% in constant currency, supported by strong demand for immunoglobulin products. Performance was further aided by the rollout of Biotest’s next-generation IVIG Yimmugo in the U.S. and continued momentum from Gamunex in key U.S. and European markets. These gains were partly offset by weaker pricing in albumin in China and tougher comparisons in Alpha-1 and Specialty Proteins.